Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Zorubicin |
Anthracycline / Anthracenedione | Both (Solid & Hematologic) | ||
|
Molecule
Zorubicin
Therapeutic Category
Cytotoxic Chemotherapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anthracycline / Anthracenedione |
||||
Abexinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Abexinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Actinium-225 PSMA |
Radiotherapeutic / Radiodiagnostic Agent | Both (Solid & Hematologic) | ||
|
Molecule
Actinium-225 PSMA
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
||||
Adavosertib |
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) | Solid Tumour | ||
|
Molecule
Adavosertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
||||
Adebrelimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Adebrelimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Afamitresgene Autoleucel |
Engineered TCR T-Cell Therapy, MAGE-A4 (HLA-A*02 restricted) | Solid Tumour (Sarcoma) | ||
|
Molecule
Afamitresgene Autoleucel
Therapeutic Category
Cellular Therapy
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Engineered TCR T-Cell Therapy, MAGE-A4 (HLA-A*02 restricted) |
||||
Afatinib |
EGFR / HER2 Tyrosine Kinase Inhibitor | Solid Tumour | ||
|
Molecule
Afatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
||||
Aflibercept |
Anti-VEGF / VEGFR Agent | Solid Tumour | ||
|
Molecule
Aflibercept
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
||||
Afuresertib |
AKT Inhibitor | Solid Tumour | ||
|
Molecule
Afuresertib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
||||
Aldesleukin (IL-2) |
Interferon / Interleukin | Both (Solid & Hematologic) | ||
|
Molecule
Aldesleukin (IL-2)
Therapeutic Category
Immunotherapy (Cytokine)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Interferon / Interleukin |
||||
Alectinib |
ALK / ROS1 / NTRK Inhibitor | Solid Tumour | ||
|
Molecule
Alectinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
||||
Alemtuzumab |
Anti-CD52 mAb | Hematologic (CLL) | ||
|
Molecule
Alemtuzumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (CLL)
Drug Class / Mechanism
Anti-CD52 mAb |
||||
ZorubicinCytotoxic Chemotherapy |
|
|
Therapeutic Category
Cytotoxic Chemotherapy
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anthracycline / Anthracenedione |
|
AbexinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
Actinium-225 PSMARadiopharmaceutical / Nuclear Medicine |
|
|
Therapeutic Category
Radiopharmaceutical / Nuclear Medicine
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Radiotherapeutic / Radiodiagnostic Agent |
|
AdavosertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
DNA Damage Response Inhibitor (WEE1/ATR/CHK1) |
|
AdebrelimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
Afamitresgene AutoleucelCellular Therapy |
|
|
Therapeutic Category
Cellular Therapy
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Engineered TCR T-Cell Therapy, MAGE-A4 (HLA-A*02 restricted) |
|
AfatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
EGFR / HER2 Tyrosine Kinase Inhibitor |
|
AfliberceptTargeted Therapy (Antibody) |
|
|
Therapeutic Category
Targeted Therapy (Antibody)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-VEGF / VEGFR Agent |
|
AfuresertibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
AKT Inhibitor |
|
Aldesleukin (IL-2)Immunotherapy (Cytokine) |
|
|
Therapeutic Category
Immunotherapy (Cytokine)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Interferon / Interleukin |
|
AlectinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
|
AlemtuzumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (CLL)
Drug Class / Mechanism
Anti-CD52 mAb |
|